nach oben

PharmacoEconomics

Erschienen in:

01.02.2004 | Correspondence

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors’ Reply

verfasst von: Nancy Thiry, Philippe Beutels, Pierre Van Damme, Eddy Van Doorslaer

Erschienen in: PharmacoEconomics | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Excerpt

Hammerschmidt et al. present the results of their own new economic evaluation of varicella vaccination in Germany[1] and question the conclusions of our review of the literature.[2] We have the impression, however, that Hammerschmidt et al. have somewhat misread — and definitely misinterpreted — our review. We still consider our discussion and conclusion to be appropriate. …

Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine varicella vaccination in Germany. Vaccine 2003; 21: 1256–67CrossRef

Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38CrossRef

Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17 (2): 142–51CrossRef

Galil K, Brown C, Lin F, et al. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis 2002; 21: 931–4CrossRef

Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127 (2): 305–14CrossRef

Schmitt III, Booy R, Weil-Oliver C, et al. Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis 2003; 3: 103–8CrossRef

Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 2003; 70: S31–7CrossRef

Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140: 81–104CrossRef

Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. Review. J Infect 2002; 44: 221–9

10.

Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319: 1462–7CrossRef

11.

Seward IF, Jumaan AO, Galil K, et al. Varicella vaccine and shingles. JAMA 2002; 287: 2211–2CrossRef

12.

Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500–7CrossRef

13.

Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678–82CrossRef

14.

Edmunds WJ, Brisson M, Gay NJ, et al. Varicella vaccination: a double-edge sword? Commun Dis Public Health 2002; 5 (3): 185–6PubMed

15.

Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: S8–S15CrossRef

16.

Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74CrossRef

Titel: Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors’ Reply
verfasst von: Nancy Thiry
Philippe Beutels
Pierre Van Damme
Eddy Van Doorslaer
Publikationsdatum: 01.02.2004
Verlag: Springer International Publishing
Erschienen in: PharmacoEconomics / Ausgabe 2/2004
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200422020-00006

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2004

Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature

Cost of Stress Urinary Incontinence

The Generation Gap

Infliximab